Svetomir N Markovic

7041301, May 9, 2006

Nov 6, 1998

09/187385

Svetomir N. Markovic - Rochester MN, US

Mayo Foundation for Medical Education and Research - Rochester MN

A61K 45/00

4242781, 424 854, 424 851, 424 852, 424 857, 530351, 514 2

A method for reducing the recurrence of a resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition, then surgically resecting the malignant tumor. A method for treating a human patient having a non-resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition to the patient and treating the patient with effective non-surgical medical methodologies to diminish the tumor. An article of manufacture combines an α-interferon composition within a packaging material and a package label or insert indicating that administration of an immunostimulatory dosage of an α-interferon composition followed by surgical resection of a malignant tumor can be effective for treating a human patient having the malignant tumor.

8530428, Sep 10, 2013

Mar 7, 2008

12/529897

Svetomir N. Markovic - Rochester MN, US

Mayo Foundation for Medical Education and Research - Rochester MN

A61K 38/14
A61K 9/12

514 192, 514 193, 514 198, 514 211

Methods for treating cancer (e. g. , metastatic cancer to the lung or chronic lymphocytic leukemia) in patients are described that include administrating an aerosolized granulocyte macrophage colony stimulating factor to the patients. Methods for stimulating an immune response in patients also are described.

20050181377, Aug 18, 2005

Feb 13, 2004

10/779159

Svetomir Markovic - Rochester MN, US

C12Q001/68
G06F019/00
G01N033/48
G01N033/50

435006000, 702020000

Methods and compositions are described for determining the expression profile of a tumor and subsequently determining an appropriate cancer therapy. Accordingly, a database can correlate expression profile data of a particular tumor before a chemotherapeutic is administered, and after the chemotherapeutic is administered and after tumor progression, such as when a tumor has developed a resistance to the chemotherapeutic agent. The database can then be used to determine an appropriate treatment for a patient with a particular kind of tumor that expresses a particular subset of genes. The methods and compositions related to the invention can further be used to predict at least one secondary therapeutic agent, which is targeted against a gene overexpressed in tumor tissue following treatment with a primary therapy and during tumor progression.

20060104948, May 18, 2006

Dec 21, 2005

11/314227

Svetomir Markovic - Rochester MN, US

A61K 38/21

424085700

A method for reducing the recurrence of a resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition, then surgically resecting the malignant tumor. A method for treating a human patient having a non-resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition to the patient and treating the patient with effective non-surgical medical methodologies to diminish the tumor. An article of manufacture combines an α-interferon composition within a packaging material and a package label or insert indicating that administration of an immunostimulatory dosage of an α-interferon composition followed by surgical resection of a malignant tumor can be effective for treating a human patient having the malignant tumor.

20070141067, Jun 21, 2007

Feb 1, 2007

11/670326

Svetomir Markovic - Rochester MN, US

MAYO MEDICAL VENTURES - Rochester MN

A61K 48/00
C12Q 1/68
G06F 19/00
A61K 39/395

424155100, 435006000, 702020000, 514044000

Methods and compositions are described for determining the expression profile of a tumor and subsequently determining an appropriate cancer therapy. Accordingly, a database can correlate expression profile data of a particular tumor before a chemotherapeutic is administered, and after the chemotherapeutic is administered and after tumor progression, such as when a tumor has developed a resistance to the chemotherapeutic agent. The database can then be used to determine an appropriate treatment for a patient with a particular kind of tumor that expresses a particular subset of genes. The methods and compositions related to the invention can further be used to predict at least one secondary therapeutic agent, which is targeted against a gene overexpressed in tumor tissue following treatment with a primary therapy and during tumor progression.

20090297471, Dec 3, 2009

May 26, 2005

11/569653

Svetomir N. Markovic - Rochester MN, US
Luis F. Porrata - Rochester MN, US

MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN

A61K 35/12
A61K 38/20
A61K 38/21
A61K 35/18
A61P 35/00

424 852, 424 851, 424 855, 424 857, 424 937, 424 9373

Materials and methods for obtaining populations of lymphocytes and administering the population of lymphocytes to a subject are disclosed herein. In particular, disclosed herein are materials and methods for obtaining lymphocyte populations that contain at least about 0.5×10NK cells per kilogram weight of the subject from which the cells are harvested.

20100047234, Feb 25, 2010

Mar 14, 2008

12/295834

Svetomir N. Markovic - Rochester MN, US

A61K 39/395

4241331

This document provides methods and materials related to treating skin cancer. For example, methods and materials relating to the use of a taxane compound, an alkylating agent, and an anti-VEGF polypeptide antibody to treat skin cancer are provided.

20110150902, Jun 23, 2011

Dec 27, 2010

12/979105

Svetomir N. Markovic - Rochester MN, US

A61K 39/395
A61K 31/56
A61K 39/00
A61P 29/00
A61P 35/00

4241581, 514171, 4241841, 4242771

This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided.